Paroxysmal nocturnal hemoglobinuria

Known as: Hemoglobinuria, Paroxysmal Nocturnal, Nocturnal Paroxysmal Hemoglobinuria, PNH 
A rare disorder in which red blood cells are easily destroyed by certain immune system proteins. Symptoms include blood clots, and red or brownish… (More)
National Institutes of Health

Related topics

Related topics

8 relations
Cold paroxysmal hemoglobinuriaHematopoietic and Lymphoid CellHematopoietic and Lymphoid TissuePAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1
(More)

Broader (2)

HemoglobinuriaHemoglobinuria, Paroxysmal

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Paroxysmal nocturnal hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
How I treat paroxysmal nocturnal hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.
The natural history of paroxysmal nocturnal hemoglobinuria (PNH) clinical subcategories (classic PNH and aplastic anemia [AA]/PNH… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders. In paroxysmal nocturnal… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
BACKGROUND We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.
In paroxysmal nocturnal hemoglobinuria (PNH), acquired somatic mutations in the PIG-A gene give rise to clonal populations of red… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Natural history of paroxysmal nocturnal hemoglobinuria.
BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by intravascular hemolysis and venous thrombosis, is… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria is an acquired hematopoietic disease characterized by abnormal blood cell populations in… (More)
Is this relevant?